Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.

David Z I Cherney Eleuterio Ferrannini Guillermo E UmpierrezAnne L PetersJulio RosenstockDavid R PowellMichael J DaviesPhillip BanksRajiv Agarwal

Published in: Diabetes, obesity & metabolism (2023)

After 26 weeks, HbA1c was significantly reduced with sotagliflozin 400 but not 200 mg compared with placebo in this CKD3 cohort. UACR in patients with at least A2 albuminuria was reduced with each of the two doses at 26 weeks, but changes were not sustained at week 52. The safety findings were consistent with previous reports (NCT03242252).

Keyphrases

chronic kidney disease
end stage renal disease
gestational age
placebo controlled
emergency department
clinical trial
peritoneal dialysis